Nextstellis (Drospirenone/Estetrol) Patent Expiration, LOE Window & CMS Spending

Nextstellis (Drospirenone/Estetrol) by Mayne: FDA Orange Book LOE 2043-10-01, 0 AB generics, $11.3M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorMayne
FDA Application & PathwayN214154 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2043-10-01
Orange Book Patents (*PED Extensions)7 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$11.3M
2024 Medicare Part D Spend$94K
2024 Medicaid Spend$11.2M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel